Oppenheimer analyst Matthew Biegler downgraded Blueprint Medicines (BPMC) to Perform from Outperform without a price target after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right. The deal is a solid outcome for shareholders, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank
- Blueprint Medicines downgraded to Hold from Buy at Needham
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Blueprint Medicines downgraded to Neutral from Outperform at Wedbush
- Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA